Highlights of Ophthalmology

Register      Login

VOLUME 40 , ISSUE 1ENG ( Feb-2012, 2012 ) > List of Articles

REVIEW ARTICLE

Bevacizumab and Cataract Surgery in AMD

Jose M. Ruiz-Moreno, Javier A. Montero, Pedro Amat-Peral, Francisco L. Lugo

Citation Information : Ruiz-Moreno JM, Montero JA, Amat-Peral P, Lugo FL. Bevacizumab and Cataract Surgery in AMD. 2012; 40 (1ENG):20-24.

DOI: 10.5005/hoo-10101-40105

Published Online: 25-02-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: Inflammatory mediators such as those released by surgery may induce choroidal neovasculari- zation (CNV) re-activation. We report the use of intravitreal bevacizumab associated with cataract surgery to prevent CNV re-activation in patients with previously treated CNV associated with Age Related Macular Degeneration (AMD). Patients and Methods: Interventional case series of fourteen eyes from 14 patients presenting cataracts who had been previously treated for wet AMD. The patients underwent clear cornea phacoemulsification with intraocular lens implantation. An intravitreal injection of 1.25 mg (0.05 ml) bevacizumab was performed by the end of the procedure. The historical data of nine patients previously treated for wet AMD who had undergone cataract surgery at our hospital were used as control group. The results were evaluated in terms of visual acuity improvement and reactivation of CNV as determined by the appearance of fluid in optical coherence tomography (OCT). Results: Best corrected visual acuity (BCVA) significantly improved after surgery (p=0.000, Student t test for paired data). Mean follow-up after cataract surgery was 13.5 months (SD 6.5, range 6 to 25 months). CNV re-activation or new CNV lesions were not observed in any case during follow-up in the treated group. CNV re- activation was observed in two cases at 4 and 6 months after cataract surgery in the control group. Conclusion: Intravitreal bevacizumab injected immediately after cataract surgery may prevent CNV re-activation in patients with previously treated CNV secondary to AMD.


PDF Share
  1. Velez G, Weiter JJ (2002) Cataract extraction and age-related macular degeneration: associations, diagnosis and management. Semin Ophthalmol 17:187-95.
  2. Tu KL, Kaye SB, Sidaras G, Taylor W, Shenkin A (2007) Effect of intraocular surgery and ketamine on aqueous and serum cytokines. Mol Vis 13:1130-7.
  3. Patel JI (2007) Is cataract surgery a risk factor for progression of macular degeneration? Curr Opin Ophthalmol 18:9-12.
  4. Ruiz-Moreno JM, Montero JA, Zarbin MA (2007) Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 27:458-61.
  5. Ruiz-Moreno JM, Coco RM, Garcia-Arumi J, Xu X, Zlateva G (2008) Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin 24:2103-11.
  6. Patel JI, Hykin PG, Cree IA (2006) Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. Br J Ophthalmol 90:697-701.
  7. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Jr., Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495-511.
  8. Spaide RF, Laud K, Fine HF, Klancnik JM, Jr., Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-90.
  9. Singh A, Stewart JM (2007) AMD: Should we screen? Eye 21:302-3.
  10. Bakri SJ, Kitzmann AS (2007) Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 143:505-7.
  11. Hooper CY, Lamoureux EL, Lim L, Fraser-Bell S, Yeoh J, Harper CA, Keeffe JE, Guymer RH (2009). Cataract surgery in high-risk age-related macular degeneration: a randomized controlled trial. Clin Experiment Ophthalmol 37:570-6.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.